Table 2.
Comparison of baseline and clinical characteristics between patients who shifted versus those who did not switch to NOACs during follow-up
| Shift to NOACs during follow-up | |||
|---|---|---|---|
| Shifted N = 3737 % (n) |
Did not Shift N = 3,877 % (n) |
p-value | |
| Age (years), Mean (SD) | 73.5 (8.8) | 73.3 (11.2) | < 0.001 |
| Median (IQR) | 69.3 (62.6; 75.6) | 68.3 (60.2; 75.7) | |
| Female sex | 47.9% (1791) | 42.9% (1662) | < 0.001 |
| Immigration ≥ 1990 | 39.6% (1481) | 38.5% (1494) | 0.339 |
| SES score, Mean (SD) | 5.85 (1.76) | 5.90 (1.79) | 0.207 |
| Median (IQR) | 6 (5; 7) | 6 (5; 7) | |
| District | |||
| North | 17.7% (661) | 18.9% (734) | < 0.001 |
| Sharon | 17.1% (639) | 17.7% (685) | |
| South | 22.1% (827) | 18.3% (708) | |
| Center | 18.7% (700) | 21.0% (813) | |
| Jerusalem/ Hashfela | 24.4% (910) | 24.2% (937) | |
|
CHADS2 score Mean (SD), |
2.29 (1.21) | 2.18 (1.36) | < 0.001 |
| Median (IQR) | 2 (1; 3) | 2 (1; 3) | |
| CHADS2 risk levels | |||
| 0 | 3.9% (146) | 9.1% (352) | < 0.001 |
| 1 | 22.2% (831) | 24.1% (934) | |
| ≥ 2 | 73.9% (2760) | 66.8% (2591) | |
| CHA2DS2 VASC score Mean (SD) | 3.92 (1.59) | 3.68 (1.80) | < 0.001 |
| Median (IQR) | 4 (3; 5) | 4 (2; 5) | |
| Baseline comorbidity | |||
| Congestive heart failure | 18.0% (672) | 23.3% (902) | < 0.001 |
| Ischemic heart disease | 34.1% (1275) | 35.4% (1371) | 0.265 |
| Myocardial infarction | 13.8% (516) | 14.6% (566) | 0.339 |
| IHD non-MI | 23.3% (870) | 23.7% (919) | 0.683 |
| Cerebrovascular accident | 13.8% (514) | 13.3% (516) | 0.593 |
| Transient ischemic attack | 7.4% (276) | 6.7% (260) | 0.265 |
| Peripheral arterial disease | 7.5% (279) | 8.2% (317) | 0.266 |
| Chronic kidney disease | 46.3% (1732) | 43.6% (1690) | 0.017 |
| Diabetes mellitus | 40.4% (1509) | 33.4% (1293) | < 0.001 |
| Hyperlipidemia | 88.8% (3318) | 83.2% (3224) | < 0.001 |
| Hypertension | 87.9% (3284) | 79.9% (3097) | < 0.001 |
| Chronic obstructive pulmonary disease | 2.9% (110) | 3.2% (123) | 0.608 |
| Medications | |||
| ACE inhibitors | 35.4% (1322) | 33.2% (1287) | 0.1 |
| ARBs | 52.2% (1950) | 48.3% (1871) | 0.048 |
| Beta blockers | 20.3% (760) | 17.7% (685) | 0.001 |
| Ca blockers | 45.6% (1703) | 44.0% (1705) | 0.003 |
| Diuretic | 13.8% (515) | 11.7% (455) | 0.169 |
| Nitrates | 1.0% ( 36) | 1.0% ( 37) | 0.008 |
| Other antiplatelets | 4.1% (152) | 2.6% ( 99) | 0.999 |
| Aspirin | 30.3% (1133) | 25.6% (993) | < 0.001 |
| Incident 2012–2015 | 34.1% (1274) | 27.9% (1081) | < 0.001 |
For prevalent cases, the status of all time-dependent factors is shown for 01/01/2012. For incident cases 2012–2015, the status at index date is shown
VKA: vitamin K antagonists, NOAC: new oral anticoagulants, SES: socioeconomic status, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, SD: standard deviation, CHADS: congestive heart failure, hypertension, age>75, diabetes mellitus, stroke/transient ischemic event; scale of 0 (lowest risk) to 6 (highest risk). CHA2DS2-VASc: Congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic event, sex, vascular disease history; scale of 0 (lowest risk) to 9 (highest risk)
Bold means statistically significant, i.e. p < 0.05